CTCL Publications

Various publications the Clinical Translational Core Lab (CTCL) has contributed to over the years.

2017
Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BRi, Chuang E, Cigler T, Moore A et al.. 2017. Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.. Clin Cancer Res. 23(3):666-6760.
2015
Nackos ENicole, Kornhauser N, Ward MM, Cigler T, Moore A, Andreopoulou E, Chan N, Fitzpatrick V, Schneider SE, Wiener A et al.. 2015. Altering the Tumor Microenvironment: A Phase II Study of Copper-depletion using Tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence.. Journal of Clinical Oncology 2015 33:15_suppl, 11008-11008 (Oral Presentation)
Stanton SE, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, Donovan D, Scheff RJ, Cigler T, Moore A et al.. 2015. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.. BMC Cancer. 15:267.
2014
Ebenezer GJ, Carlson K, Donovan D, Cobham M, Chuang E, Moore A, Cigler T, Ward M, Lane ME, Ramnarain A et al.. 2014. Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients.. Ann Clin Transl Neurol. 1(9):639-49.
Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F et al.. 2014. Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.. Invest New Drugs. 32(3):542-8.
2013
Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB et al.. 2013. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.. Clin Cancer Res. 19(6):1534-46.
Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV et al.. 2013. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.. Ann Oncol. 24(6):1491-8.
2012
Jain S, Ward MM, O'Loughlin J, Boeck M, Wiener N, Chuang E, Cigler T, Moore A, Donovan D, Lam C et al.. 2012. Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.. Breast Cancer Res Treat. 132(1):235-42.
2011
Ward M.M., Mark T., Manco M., Stern J., O'Loughlin J., Shore T.B., Pearse R.N., Jayabalan D., Skerrett D., Chen-King S. et al.. 2011. High-yield of CD34+ cells with bortezomib-basedmobilization regimen is associated with specific genomic expression patterns, decrease in SDF-1 plasma levels and up-regulation of CXCR4 in multiple myeloma (MM) patients..
Jain S, Ward MM, O'Loughlin J, Boeck MA, Wiener N, Chuang E, Cigler T, Moore A, Donovan D, Lam C et al.. 2011. Incremental increase in VEGFR1+ and VEGFR2+ hemangiogenic cells predict relapse and tumor response in breast cancer (BC) patients.. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research.

Contact Information

Abbreviation Library